Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
HIV or Tuberculosis
and you are
between 18 and 60
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

To describe the pharmacokinetics of rifabutin 150 mg once daily versus rifabutin 300 mg thrice weekly in combination with LPV/r 400/100mg based HAART in HIV/TB infected patients

Provided treatments

  • Drug: Lopinavir/r will be supplied by NHSO/GPO
  • Drug: Rifabutin
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02415985. The sponsor of the trial is The HIV Netherlands Australia Thailand Research Collaboration and it is looking for 40 volunteers for the current phase.
Official trial title:
A Pilot Study of the Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly With Lopinavir/Ritonavir Based HAART in HIV/TB Co-infected Patients